Empower Advisory Group LLC Purchases 6,747 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Empower Advisory Group LLC boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 275,851 shares of the medical research company's stock after buying an additional 6,747 shares during the period. Empower Advisory Group LLC owned 0.54% of Charles River Laboratories International worth $50,922,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after buying an additional 3,738,018 shares during the period. Mizuho Securities USA LLC increased its stake in shares of Charles River Laboratories International by 2,336.4% in the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company's stock worth $19,081,000 after acquiring an additional 92,895 shares in the last quarter. Premier Fund Managers Ltd lifted its position in Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company's stock valued at $49,573,000 after acquiring an additional 90,000 shares during the period. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares during the period. 98.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on CRL shares. UBS Group reiterated a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Bank of America lowered their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. Finally, Evercore ISI upped their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $195.71.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $0.86 during trading hours on Friday, reaching $163.11. The company had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The business has a fifty day moving average price of $172.84 and a 200-day moving average price of $188.37. Charles River Laboratories International, Inc. has a one year low of $150.79 and a one year high of $275.00. The firm has a market cap of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).